Alkermes PLC
Uždarymo kaina
SektoriusSveikatos priežiūra
50.18 4.32
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
47.88
Max
51.57
Pajamos | -116M -66M |
|---|---|
Pardavimai | 8.4M 393M |
P/E Sektoriaus vid. | 51.133 50.958 |
Pelnas, tenkantis vienai akcijai | 0.38 |
Pelno marža | -16.92 |
Darbuotojai | 2,050 |
EBITDA | -98M -22M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +4.01% upside |
Kitas uždarbis | 2026-07-28 |
|---|
Rinkos kapitalizacija | 2B 7.7B |
|---|---|
Ankstesnė atidarymo kaina | 45.86 |
Ankstesnė uždarymo kaina | 50.18 |
Naujienos nuotaikos
By Acuity
10%
90%
13 / 342 reitingas Healthcare
Alkermes PLC Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
